Tevogen Bio Holdings Inc

Stock Chart, Company Information, and Scan Results

$1.01(as of Aug 13, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Tevogen Bio Holdings Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$1.01
Ticker SymbolTVGN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees18
CountyUSA
Market Cap$186.4M
EBIDTA-34.2M
10-Day Moving Average0.97
P/E Ratio-4.61
20-Day Moving Average1.04
Forward P/E Ratio0.00
50-Day Moving Average1.16
Earnings per Share-0.22
200-Day Moving Average1.26
Profit Margin-2,614.08%
RSI45.10
Shares Outstanding193.7M
ATR0.10
52-Week High3.09
Volume1,341,776
52-Week Low0.26
Most Recent Support Level0.83
Book Value-7.7M
Most Recent Resistance Level1.02
P/B Ratio-21.12
Upper Keltner1.26
P/S Ratio411.06
Lower Keltner0.81
Debt-to-Equity Ratio1.26
Next Earnings DateUnknown
Cash Surplus-6.7M
Next Ex-Dividend DateUnknown

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Tevogen Bio Holdings Inc In Our Stock Scanner

As of Aug 14, 2025
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.